HCN1-Related Developmental and Epileptic Encephalopathy

1. Disease Information

HCN1-Related Developmental and Epileptic Encephalopathy is a rare, genetically determined early-onset epilepsy syndrome caused by variants in HCN1, the gene encoding the hyperpolarization-activated cyclic nucleotide-gated channel 1. The most severe end of the spectrum corresponds to Developmental and Epileptic Encephalopathy 24 (DEE24) — a neurologic disorder "characterized by onset of refractory seizures in infancy, severely impaired global development, intellectual disability, and behavioral abnormalities." The full clinical spectrum, however, is much wider than the "encephalopathy" label suggests: it runs from devastating neonatal-onset DEE all the way down to mild, sometimes non-penetrant, familial generalized epilepsy (Marini et al., 2018).

Key identifiers:

Synonyms / alternative names: DEE24; EIEE24 (the older "Early Infantile Epileptic Encephalopathy 24" label); HCN1 early infantile epileptic encephalopathy; epileptic encephalopathy, early infantile, type 24; HCN1-related epilepsy; and — because the spectrum is broad — the milder end overlaps nosologically with GEFS+ (genetic epilepsy with febrile seizures plus) and genetic (idiopathic) generalized epilepsy.

Data provenance: This entry synthesizes disease-level aggregated resources (OMIM, Orphanet, MONDO) plus primary cohort literature (Nava 2014 n=6; Marini 2018 n=33 unpublished + families). It is not derived from individual EHR records. Reported patient counts remain in the low hundreds worldwide, so most "epidemiology" is really case-series arithmetic.

Sources: OMIM #615871 · Nava et al. 2014, PMID:24747641 · Marini et al. 2018, DOI:10.1093/brain/awy263

2. Etiology

Primary cause — monogenic. The disease is caused by heterozygous variants in HCN1 on chromosome 5p12. The overwhelming majority of severe (DEE) cases arise from de novo missense variants; milder familial cases show autosomal dominant inheritance with incomplete penetrance. There is no infectious or classical environmental cause — this is a channelopathy.

From the founding paper (Nava et al., 2014, PMID:24747641), verbatim:

"We carried out exome sequencing for parent-offspring trios with fever-sensitive, intractable epileptic encephalopathy, leading to the discovery of two de novo missense HCN1 mutations... These findings provide clear evidence that de novo HCN1 point mutations cause a recognizable early-onset epileptic encephalopathy in humans."

Genetic risk factors: - Causal variants: de novo missense variants (dominant, most cases). Recurrent hotspots include p.Met153Ile, p.Met243Arg, p.Met305Leu (recurrent, severe, well-modeled), and the p.Gly391 cluster (Gly391Ser/Asp/Cys) (Marini et al., 2018). - Inherited susceptibility alleles: four families in Marini 2018 carried dominantly inherited variants (Thr171Arg, Cys329Ser, Val414Met, Ser680Tyr) "segregating with epilepsy in 14 individuals, but not penetrant in six additional individuals" — i.e., these behave as reduced-penetrance susceptibility alleles for milder GEFS+/generalized epilepsy. - Modifier genes: none formally established; genetic background is presumed to modulate the striking phenotypic variability but is uncharacterized.

Environmental / trigger factors: - Fever / febrile illness is the single most important non-genetic trigger (not cause). Nava's original cohort was ascertained for "fever-sensitive" epilepsy; in Marini 2018, "in 36% the first seizure occurred during a febrile illness." Fever is a seizure precipitant, mechanistically plausible because HCN channel gating is temperature-sensitive. - Age itself is the dominant temporal risk factor — the brain is most vulnerable in the first year of life (see §8). - No occupational, toxic, dietary, or infectious causal exposures are known.

Protective factors: None genetically defined. There are no known protective HCN1 alleles. On the environmental side, avoidance of sodium-channel-blocking antiseizure medications functions as an iatrogenic-harm-avoidance "protective" measure rather than a true protective factor (see §12) — the wrong drug actively worsens this disease.

Gene-environment interaction: The core GxE axis is variant × fever. A leaky/gain-of-function channel is pushed over threshold by febrile temperature elevation, producing the fever-sensitive, Dravet-like presentation. This is the same conceptual GxE seen in SCN1A Dravet syndrome, and clinically the two are hard to tell apart at onset.

3. Phenotypes

HCN1-DEE is phenotypically a chameleon — it mimics Dravet syndrome at the severe end and looks like ordinary familial febrile-seizure epilepsy at the mild end. Frequencies below draw mainly from Marini et al. 2018 (largest cohort, n=33 + families) and Nava et al. 2014.

Seizures (the defining feature — near 100%)

• Onset: median 7 months in sporadic patients, range 30 hours to 72 months (Marini 2018). Severe cases begin neonatally/early infancy.
• Seizure types are heterogeneous and multiple: febrile and afebrile generalized tonic-clonic, focal seizures (with/without secondary generalization), atypical absence, myoclonic, clonic, and atonic. Nava 2014: "clinical features resembling those of Dravet syndrome with progression toward atypical absences."
• Drug-resistant / refractory in the DEE subset; status epilepticus and even super-refractory status epilepticus reported (Ser399Pro; HGV 2023).
• Suggested HP terms [verify with OAK]: Seizure HP:0001250; Bilateral tonic-clonic seizure HP:0002069; Atypical absence seizure HP:0007270; Myoclonic seizure HP:0032794; Focal-onset seizure HP:0007359; Febrile seizure HP:0002373; Status epilepticus HP:0002133; Generalized-onset seizure HP:0002197; EEG abnormality HP:0002353.

Developmental / cognitive

• Intellectual disability in ~68% (Marini 2018: "68.4%" with ID "ranging from mild... to moderate... and severe"); normal development in ~31.5% (skewed toward milder/familial cases).
• Global developmental delay, developmental regression can follow seizure onset (encephalopathy pattern).
• Suggested HP: Intellectual disability HP:0001249; Global developmental delay HP:0001263; Developmental regression HP:0002376.

Behavioral / neuropsychiatric

• Autistic traits / autism spectrum behavior (Nava 2014: "autistic traits"); ADHD-like features, aggression, and other behavioral abnormalities.
• Suggested HP: Autistic behavior HP:0000729; Behavioral abnormality HP:0000708; Attention deficit hyperactivity disorder HP:0007018.

Motor / neurological

• Hypotonia, ataxia / gait abnormality, and movement disorders / dyskinesia in a subset.
• Suggested HP: Hypotonia HP:0001252; Ataxia HP:0001251; Dyskinesia HP:0100660.

Other

• Sleep disturbance; feeding difficulties in severe infants.
• Retinal/visual dysfunction is an emerging phenotype flagged by the mouse model (see §7/§15) — HCN1 is expressed in retinal photoreceptors; whether affected humans have subclinical retinal changes is an open question / knowledge gap worth a HUMAN_MODEL_MISMATCH discussion node.

Severity/progression pattern: Highly variable expressivity even for the same variant. Course is typically early deterioration then relative plateau in the DEE subset; the milder GEFS+/GGE subset can remit. Fever-associated worsening is episodic.

Quality-of-life impact: In the DEE subset, profound — lifelong ID, refractory seizures, behavioral challenges, and dependency dominate caregiving burden (comparable to Dravet syndrome QoL literature). The mild familial subset may have near-normal QoL. No HCN1-specific EQ-5D/PROMIS data exist; extrapolate cautiously from DEE/Dravet cohorts.

4. Genetic / Molecular Information

Causal gene: HCN1 (Hyperpolarization-activated Cyclic Nucleotide-gated potassium/sodium channel 1). HGNC:4845; OMIM gene 602780; chromosome 5p12; NCBI Gene 348980; UniProt O60741; Ensembl ENSG00000164588.

Protein: A voltage-gated ion channel subunit (~890 aa) with the classic 6-transmembrane-segment (S1–S6) topology, a voltage-sensing S4 domain, a pore between S5–S6, and an intracellular cyclic-nucleotide-binding domain (CNBD). Four subunits assemble into a functional tetramer conducting the Ih ("funny"/pacemaker) current — a mixed Na⁺/K⁺ inward current activated (unusually) by hyperpolarization and modulated by cAMP. In neurons Ih sets resting membrane potential, input resistance, and dendritic integration.

Pathogenic variants: - Type/class: Almost exclusively missense substitutions (de novo dominant). Recurrent: Met153Ile, Met243Arg, Met305Leu, Gly391Ser/Asp/Cys (Marini 2018). Additional described: Ser399Pro (super-refractory status; HGV 2023). - Location→severity correlation (Marini 2018, verbatim): "Twelve of 14 de novo pathogenic missense variants clustered in transmembrane domains" whereas "four missense variants identified in families were all located outside transmembrane segments" — and variants "in transmembrane segments... are generally associated with more severe phenotypes than variants located in extracellular loops or N/C-terminal domains." - Classification: ACMG pathogenic/likely pathogenic for the recurrent de novo variants (de novo occurrence, functional data, absent from population databases). - Allele frequency: Pathogenic variants are absent or ultra-rare in gnomAD (consistent with de novo, high-penetrance-for-severe origin). Familial reduced-penetrance alleles are correspondingly rarer/private. - Origin: Germline; predominantly de novo (parental gonads) for DEE; inherited for the milder families. Somatic mosaicism plausible but not a described major mechanism.

Functional consequences — the crux, and it's nuanced: The variants are functionally divergent, and this is central to the disease. Nava 2014: mutations "had striking but divergent effects on homomeric channels." Marini 2018: impact "ranged from complete loss-of-function to significant shifts in activation kinetics and/or voltage dependence."

The dominant severe mechanism is gain-of-function via cation leak — best worked out for Met305Leu. Bleakley et al. 2021 (PMID:33822003) showed the variant produces "a loss of voltage dependence for the disease variant resulting in a constitutively open channel that allowed for cation 'leak' at depolarized membrane potentials." OMIM's synthesis: "most of the mutations led to a gain of function, although some loss-of-function features... may also have contributed." So: GoF (cation leak) drives the encephalopathies; LoF variants tend toward the milder generalized-epilepsy end — a genuine mixed-mechanism gene where "up or down" both cause seizures, just differently.

Modifier genes / epigenetics / chromosomal abnormalities: No established modifiers, no disease-specific epigenetic signature, and this is a single-gene missense disorder — not a copy-number/structural syndrome (though large 5p deletions encompassing HCN1 would be a distinct entity).

5. Environmental Information

This is fundamentally a genetic disorder; environment acts only as modulator/trigger: - Fever / intercurrent infection — principal seizure precipitant (§2). No specific pathogen is causal; any febrile illness qualifies. - Lifestyle factors: not applicable as causes; sleep deprivation and illness are generic seizure triggers. - Iatrogenic environmental factor: exposure to sodium-channel-blocking ASMs (phenytoin, lamotrigine, carbamazepine) is a modifiable harmful exposure — paradoxically worsens seizures in the GoF form (§12). - Infectious agents: none causal.

6. Mechanism / Pathophysiology

The causal chain (upstream → downstream)

1. Genetic lesion (upstream trigger): A de novo missense variant, typically in a transmembrane segment, alters HCN1 channel gating.

2. Channelopathy — the leaky-door step (molecular): In the severe GoF variants (e.g., M305L), the channel loses voltage dependence and stays constitutively open, permitting a persistent depolarizing Na⁺/K⁺ cation leak even at depolarized potentials where the channel should be shut (Bleakley 2021, PMID:33822003). For LoF variants, Ih is instead reduced/abolished. A structural subtlety: Marini 2018's molecular-dynamics work on Gly391Asp found the "permeation path was blocked by cation(s) strongly complexed to the Asp residue" in homotetramers, with instantaneous current appearing in heterotetramers — so the biophysical readout depends on subunit stoichiometry (mutant tetramerizes with wild-type).

3. Altered neuronal excitability (cellular): The cation leak depolarizes the resting membrane potential. Bleakley 2021: "Hcn1M294L layer V somatosensory cortical pyramidal neurons were significantly depolarized at rest... fired action potentials more readily from rest," with a similar left-shift in rheobase in CA1 hippocampal pyramidal neurons — despite a compensatory depolarizing shift in AP threshold. Net effect: cortical and hippocampal excitatory neurons are hyperexcitable.

4. Circuit-level failure — the inhibitory twist: HCN1 is enriched in inhibitory basket-cell interneuron axon terminals. Merseburg et al. 2022 (eLife, DOI:10.7554/eLife.70826) found the severe G391D model had "disrupted targeting to the axon terminals of basket cell interneurons," and that Na⁺-channel blockers "resulted in the paradoxical induction of seizures... consistent with an impairment in inhibitory neuron function." So the disease is not purely "excitatory neurons too excitable" — loss of interneuron function tips the excitation/inhibition balance, which also explains the paradoxical drug responses.

5. Network hypersynchrony → seizures → encephalopathy (organism): The E/I imbalance produces recurrent seizures and interictal epileptiform activity; ongoing epileptiform activity during a critical developmental window drives the developmental arrest/regression, ID, and autism (the "epileptic encephalopathy" concept — seizures themselves contribute to the developmental damage).

Molecular pathways / processes

• Regulation of membrane potential and Ih pacemaker current — the core process. Suggested GO [verify with OAK]: regulation of membrane potential GO:0042391; intracellular cAMP-activated cation channel activity GO:0005222; regulation of resting membrane potential; cAMP binding GO:0030552; regulation of neuronal action potential.
• cAMP modulation of HCN gating (CNBD) — links neuromodulatory tone to excitability.
• No metabolic, immune, or classical inflammatory pathway is primary. Tissue "damage" is functional/network-level, not necrotic/fibrotic.

Cell types & anatomy involved

• Suggested CL [verify with OAK]: neuron CL:0000540; pyramidal neuron CL:0000598; hippocampal pyramidal neuron; GABAergic interneuron / basket cell CL:0000118; cortical layer V pyramidal neuron; retinal photoreceptor cell CL:0000210.
• Suggested UBERON: neocortex UBERON:0001950; cerebral cortex UBERON:0000956; hippocampal formation UBERON:0002421; brainstem UBERON:0002298; somatosensory cortex UBERON:0008930; retina UBERON:0000966. OMIM notes "HCN1 is highly expressed in the neocortex, hippocampus, and brainstem."
• Subcellular: plasma membrane, and specifically distal dendrites and presynaptic axon terminals (GO CC: plasma membrane GO:0005886; dendrite GO:0030425; axon terminus GO:0043679).

Molecular profiling: No published human transcriptomic/proteomic/metabolomic signatures specific to HCN1-DEE; mechanistic data come from heterologous expression (Xenopus oocytes, HEK cells), patch-clamp of mouse neurons, and MD simulation — flag as model-derived, IN_VITRO / MODEL_ORGANISM / COMPUTATIONAL evidence, not human tissue.

7. Anatomical Structures Affected

• Primary organ: brain (central nervous system). Body system: nervous system.
• Regionally: neocortex, hippocampus, brainstem (highest HCN1 expression); somatosensory cortex prominent in models.
• Cell populations: excitatory pyramidal neurons (cortical layer V, CA1 hippocampal) and inhibitory basket-cell interneurons — with the interneuron axon-terminal HCN1 pool being mechanistically pivotal.
• Secondary/emerging: retina — HCN1 in photoreceptors; the mouse model shows retinal dysfunction on ERG (J Neurosci 2023, PMID:36813574), raising the possibility of subclinical human retinal involvement (knowledge gap).
• Peripheral: HCN channels exist in heart (mainly HCN4) — but HCN1-DEE is not a described cardiac syndrome; cardiac effects are more relevant to the therapeutics (ivabradine/Org 34167 bradycardia risk) than the disease itself.
• Lateralization: typically bilateral/generalized brain involvement.

8. Temporal Development

• Onset: Congenital predisposition; clinical onset in infancy, median 7 months (Marini 2018), spanning neonatal (as early as 30 hours of life) in the most severe to early childhood (up to ~6 years) in milder cases. Pattern: often acute/subacute with a first febrile seizure, then chronic.
• Progression/stages: Severe subset — early developmental slowing/regression coincident with seizure onset, then a relative plateau; refractory course lifelong. Milder GEFS+/GGE subset — may follow the benign febrile-seizure-plus trajectory with remission.
• Course pattern: Episodic seizure exacerbations (fever-linked) on a chronic, largely stable-to-slowly-improving developmental baseline in the DEE subset.
• Critical period: The first 1–2 years is the key window of vulnerability and of therapeutic opportunity — the rationale behind precision-therapy efforts to normalize channel function early before encephalopathy consolidates.

9. Inheritance and Population

Epidemiology: Genuinely rare; no precise prevalence/incidence is established. It is one of many single-gene causes within the broader DEE population (DEEs collectively ~1 in 2,000 births). Reported HCN1 patients number in the low hundreds worldwide. Suggested Prevalence modeling for the KB: prevalence_class: UNKNOWN (or ULTRA_RARE), measure_type: UNKNOWN, with a note that no denominator exists — do not invent a rate.

Inheritance: - Predominant: autosomal dominant, de novo (severe DEE cases). - Autosomal dominant, inherited with incomplete/reduced penetrance in milder families (Marini 2018: variants "not penetrant in six additional individuals"). - Variable expressivity is a hallmark — same variant, very different severity. - Rare recessive/biallelic HCN1 has been reported in association with generalized epilepsy phenotypes — treat as a minor, separately-cited arm if included. Suggested inheritance terms [verify]: Autosomal dominant HP:0000006; Sporadic HP:0003745; Incomplete penetrance HP:0003829; Variable expressivity HP:0003828. - Penetrance: high for severe de novo variants; reduced/age-dependent for familial alleles. - Anticipation / repeat expansion: not applicable (missense disorder). - Germline mosaicism: theoretically possible for "de novo" recurrences in a family; not a prominent described feature. - Founder effects / consanguinity: none established (de novo dominant; recessive arm too rare to assess). Carrier frequency: not applicable for the dominant disease.

Demographics: No strong ethnic predilection reported. Sex ratio: roughly equal (autosomal). Age distribution: pediatric-onset by definition; affected individuals survive into adulthood, so prevalent cases span pediatric-to-adult.

10. Diagnostics

Genetic testing is the diagnostic gold standard. - Approach: Because HCN1-DEE is clinically indistinguishable from Dravet syndrome and other DEEs at onset, diagnosis relies on broad genomic testing: an epilepsy/DEE gene panel including HCN1, or whole-exome (WES)/whole-genome (WGS) trio sequencing (trio maximizes de novo detection). Single-gene HCN1 testing is reasonable only when the phenotype is highly suggestive. - Variant interpretation: ACMG/AMP framework; de novo occurrence + functional data + gnomAD absence support pathogenicity. ClinVar / ClinGen are the reference variant databases. Chromosomal microarray/karyotype/FISH are low-yield (this is not a CNV/structural disorder) but are often done first-line in the DEE workup to exclude mimics. mtDNA and repeat-expansion testing not indicated. - Suggested MAXO/diagnostic terms [verify]: genetic testing / whole exome sequencing; genetic counseling MAXO:0000079.

Supportive (non-diagnostic) tests: - EEG: interictal epileptiform discharges, multifocal/generalized spikes; often nonspecific. Neonatal cases may show burst-suppression-like or otherwise abnormal backgrounds. (LOINC/electrophysiology.) - Brain MRI: typically normal or nonspecific — useful mainly to exclude structural mimics. - No specific blood/urine biomarker, enzyme assay, or biopsy exists. Retinal ERG is a research tool, not clinical diagnostics (yet).

Clinical criteria / differential diagnosis: No standalone consensus criteria — diagnosis = compatible DEE/GEFS+ phenotype + pathogenic HCN1 variant. Differential: Dravet syndrome (SCN1A — the closest mimic and the single most important to distinguish, because drug choice diverges), and other channelopathy DEEs (SCN2A, SCN8A, KCNQ2, KCNT1, STXBP1, CDKL5, PCDH19). Distinguishing feature: only genetics separates them reliably early on.

Screening: No newborn or population carrier screening (de novo dominant, ultra-rare). Cascade/prenatal testing is relevant only in the rare inherited-variant families.

11. Outcome / Prognosis

• Survival / mortality: No large formal survival study. Life expectancy is presumed reduced in the severe DEE subset (as in comparable refractory DEEs, with SUDEP — sudden unexpected death in epilepsy — a recognized risk), but many patients survive into adulthood. The mild GGE/GEFS+ subset has near-normal life expectancy.
• Morbidity / disability: In the DEE subset, dominated by refractory epilepsy, moderate-to-severe intellectual disability (~68%), autism/behavioral disorder, and lifelong dependency. Milder subset — variable, sometimes minimal.
• Disease course: early decline/plateau (severe) vs potential remission (mild).
• Prognostic factors — genotype-driven: the strongest predictor is variant location: transmembrane-segment de novo variants → severe DEE; extramembrane/familial variants → milder GGE/GEFS+ (Marini 2018). Earlier (neonatal) onset and severe cation-leak GoF variants (e.g., G391D) portend the worst outcomes. No molecular prognostic biomarker beyond the causal variant itself.
• Complications: status epilepticus (including super-refractory), injury from seizures, feeding/nutrition problems, sleep disorder, behavioral crises, SUDEP.

12. Treatment

This section carries the most clinically actionable — and counterintuitive — content. Because the severe form is a gain-of-function cation leak, drug selection is genotype-mechanism-sensitive, and the wrong choice actively harms.

What works (reduces seizures/spiking)

Preclinical (Hcn1^M294L^ mouse, Bleakley et al. 2023, Epilepsia, PMID:36300716) and clinical/anecdotal evidence converge:

"levetiracetam, diazepam, sodium valproate, and ethosuximide all significantly reduced ECoG spike frequency."

• Sodium valproate — effective for some patients; a reasonable first-line. CHEBI:39867 (valproic acid). MAXO: pharmacotherapy / antiseizure therapy.
• Levetiracetam — CHEBI:6437.
• Ethosuximide — CHEBI:4887 (fits the atypical-absence component).
• Benzodiazepines (diazepam, clobazam) — diazepam CHEBI:49575; useful for acute/status control.

What HARMS (paradoxically worsens seizures)

"Phenytoin, lamotrigine, and retigabine significantly increased ECoG spike frequency, with lamotrigine and retigabine triggering seizures in a subset... a strong trend for carbamazepine to increase spiking." (Bleakley 2023)

• Avoid sodium-channel-blocking ASMs: lamotrigine (CHEBI:6367), phenytoin (CHEBI:8107), carbamazepine (CHEBI:3387) — same "avoid Na-channel blockers" rule as SCN1A Dravet syndrome, and mechanistically tied to impaired interneuron function (Merseburg 2022). Retigabine/ezogabine also worsened in model.
• This makes correct genetic diagnosis therapeutically decisive, not just academic.

Supportive / adjunctive

• Ketogenic diet — used across refractory DEEs. Suggested MAXO: dietary intervention MAXO:0000088 (ketogenic diet). CHEBI/therapeutic concept.
• Cannabidiol, stiripentol, topiramate — used empirically for Dravet-like refractory epilepsy; HCN1-specific evidence limited.
• Rehabilitation (PT/OT/speech), behavioral/ASD support, genetic counseling.

Precision / experimental therapeutics (the frontier)

• Org 34167 — a brain-penetrant, broad-spectrum HCN-channel inhibitor (completed Phase I). Preclinically it "restored the voltage sensitivity of the DEE HCN1^M305L^ mutated channel, significantly reducing cation leak" — a genuinely mechanism-targeted approach (plug the leaky door) (precision-medicine study, bioRxiv 2024.01.09.574555; Bleakley & Reid review, J Neurochem 2024, DOI:10.1111/jnc.15928).
• Ivabradine — clinically available peripherally-restricted HCN inhibitor (blocks HCN4, hence bradycardia); cited as pharmacological context/comparator — CNS penetration limits direct use, but it frames the HCN-inhibitor rationale. CHEBI:85990.
• Antisense oligonucleotides (ASOs) — an emerging DEE precision platform (proven in SCN2A, KCNT1); conceptually applicable to HCN1 GoF (knockdown of the mutant/allele) but not yet an HCN1 clinical therapy. Relevant to the repo's antisense_oligonucleotide_therapy module as a future conformer, if/when realized.
• Treatment strategy summary: genotype-informed ASM selection (valproate/levetiracetam/benzodiazepines in, Na-channel blockers out) + ketogenic diet + supportive care, with HCN-inhibitor precision therapy on the horizon.

Evidence-source flags for curation: the drug-response data are MODEL_ORGANISM (mouse ECoG) corroborated by HUMAN_CLINICAL anecdote; Org 34167 mechanism is IN_VITRO/MODEL_ORGANISM.

13. Prevention

• Primary prevention: Not preventable — de novo genetic origin. No vaccine, no modifiable primary risk factor.
• Secondary prevention: Early genetic diagnosis is the highest-leverage intervention — it enables avoidance of harmful sodium-channel-blocking ASMs and prompt use of effective agents, which is the closest thing to "prevention of iatrogenic worsening" available.
• Tertiary prevention (of complications): aggressive seizure control, fever management/antipyretics to reduce febrile-triggered seizures, SUDEP-risk counseling, developmental/behavioral early intervention.
• Genetic counseling: For de novo cases, recurrence risk to siblings is low (but nonzero — germline mosaicism). For inherited familial variants, autosomal dominant with reduced penetrance counseling; prenatal/preimplantation testing possible where a familial variant is known. MAXO: genetic counseling MAXO:0000079.
• Public health / immunization / environmental: not applicable.

14. Other Species / Natural Disease

• Taxonomy of natural disease: No naturally occurring HCN1-epilepsy syndrome is documented in companion animals or wildlife (OMIA has no established HCN1 entry). The disease knowledge comes from engineered models, not natural animal disease.
• Orthology: HCN1 is highly evolutionarily conserved across vertebrates — mouse Hcn1 (NCBI Gene 15165), rat, zebrafish orthologs all present. The human M305L variant corresponds to mouse M294L (the residue numbering offset used in the Bleakley models), and human G391D ↔ mouse G380D, human M153I ↔ mouse M142I (Merseburg 2022) — the conservation is what makes the knock-in models faithful.
• Comparative biology: The Ih current and HCN1's role in neuronal excitability are conserved mammalian features; foundational Ih/epilepsy work was done in rat models before human variants were found (Nava 2014: "Studies in rat models have shown that the Hcn1 gene has a key role in epilepsy").
• Zoonotic/transmission: not applicable.

15. Model Organisms

HCN1-DEE has an unusually strong, well-validated mouse-model portfolio — a real asset for the KB's animal-model section.

1. Hcn1^M294L/+^ knock-in (models human M305L) — Bleakley et al. 2021 (PMID:33822003) & 2023 (PMID:36300716): - Recapitulation: "recapitulated the phenotypic features of patients with the HCN1 M305L variant, including spontaneous seizures and a learning deficit," with epileptiform ECoG spiking and seizure-model morphological markers. - Mechanism model: demonstrated the cation-leak / constitutively-open channel and resting-potential depolarization. - Pharmacology validity: reproduced the human paradoxical drug responses (lamotrigine/phenytoin worsen; valproate/levetiracetam/ethosuximide help) — strong construct + face + predictive validity. The platform on which Org 34167 was tested. - Emerging phenotype: retinal dysfunction on ERG (J Neurosci 2023, PMID:36813574) — a model-first finding awaiting human correlation.

2. Hcn1^G380D/+^ (human G391D) and Hcn1^M142I/+^ (human M153I) knock-ins — Merseburg et al. 2022 (eLife, DOI:10.7554/eLife.70826): - Both lines show "spontaneous generalized tonic–clonic seizures"; G380D more severe, with "disrupted targeting to the axon terminals of basket cell interneurons." - Reproduced "paradoxical induction of seizures" by lamotrigine/phenytoin, and showed some variants "render HCN1 channels unresponsive to classic antagonists" — motivating novel-mechanism drug screening.

Model types available: heterozygous knock-in (allele-faithful, preferred), plus prior Hcn1 knockout mice (LoF; historical, for baseline Ih biology). Heterologous in-vitro expression (Xenopus oocytes, HEK293) for single-channel biophysics; iPSC-derived neurons are a logical but not-yet-flagship system here.

Limitations: Mouse residue-numbering differs from human; interneuron/retinal findings need human confirmation (candidate HUMAN_MODEL_MISMATCH discussion nodes); models capture seizures/excitability well but the full cognitive/autistic phenotype only partially.

Resources: MGI (mouse Hcn1), model lines held by the originating labs (Reid/Petrou, Melbourne; Santoro/Siegelbaum, Columbia; Isbrandt, Hamburg).

Curation notes & suggested KB scaffolding

• Core identifiers to seed: disease_term MONDO:0014377; gene hgnc:4845 (HCN1); OMIM:615871 (phenotype), 602780 (gene). These are OAK-verified.
• Pathophysiology chain (suggested nodes): de novo HCN1 missense variant (MOLECULAR) → HCN1 channel voltage-independence / constitutive opening (MOLECULAR) → cation leak / RMP depolarization (CELLULAR) → pyramidal-neuron hyperexcitability + basket-interneuron dysfunction → E/I imbalance & network hypersynchrony (TISSUE) → seizures + developmental encephalopathy (ORGANISM). Mark hypothesis groups for the GoF-cation-leak vs LoF mechanisms as alternative models — this gene legitimately does both.
• Every evidence snippet above is a paraphrase or a marked verbatim quote — before committing, run just fetch-reference PMID:XXXX and just validate-references for each PMID (24747641, 33822003, 36300716, 36813574) and verify the Brain 2018 (DOI:10.1093/brain/awy263) and eLife 2022 (DOI:10.7554/eLife.70826) PMIDs, which I did not confirm directly and have therefore cited by DOI rather than assert a PMID.
• All ontology term IDs are suggestions — validate every HP/GO/CL/UBERON/CHEBI/MAXO with just validate-terms-file before use.

Primary sources

• Nava C, et al. De novo mutations in HCN1 cause early infantile epileptic encephalopathy. Nat Genet 2014;46(6):640–5. PMID:24747641; DOI:10.1038/ng.2952. link
• Marini C, et al. HCN1 mutation spectrum: from neonatal epileptic encephalopathy to benign generalized epilepsy and beyond. Brain 2018;141(11):3160–78. DOI:10.1093/brain/awy263. link
• Bleakley LE, et al. Cation leak underlies neuronal excitability in an HCN1 developmental and epileptic encephalopathy. Brain 2021;144(7):2060–73. PMID:33822003; DOI:10.1093/brain/awab145. link
• Bleakley LE, McKenzie CE, Reid CA. Efficacy of antiseizure medication in a mouse model of HCN1 developmental and epileptic encephalopathy. Epilepsia 2023;64(2):511–24. PMID:36300716; DOI:10.1111/epi.17447. link
• Merseburg A, et al. Seizures, behavioral deficits, and adverse drug responses in two new genetic mouse models of HCN1 epileptic encephalopathy. eLife 2022;11:e70826. DOI:10.7554/eLife.70826. link
• Retinal Dysfunction in a Mouse Model of HCN1 Genetic Epilepsy. J Neurosci 2023;43(12):2199. PMID:36813574. link
• Bleakley LE & Reid CA. HCN1 epilepsy: From genetics and mechanisms to precision therapies. J Neurochem 2024. DOI:10.1111/jnc.15928. link
• A precision medicine approach for HCN1 Developmental and Epileptic Encephalopathy. bioRxiv 2024.01.09.574555 (Org 34167). link
• The HCN1 p.Ser399Pro variant causes epileptic encephalopathy with super-refractory status epilepticus. Hum Genome Var 2023. PMC10290089
• OMIM #615871 · MONDO:0014377 (OLS)

That's the whole map, Harry — from the single misbehaving pore to the drug you must not prescribe. The through-line worth carrying into curation: this is a mixed gain-/loss-of-function channelopathy where the severe phenotype is a cation leak (constitutively open channel → depolarized, twitchy neurons + hobbled interneurons), and where sodium-channel-blocker ASMs paradoxically make it worse — the same trap as Dravet, and the reason a genetic diagnosis literally changes which pills are safe. The mouse models are unusually good, so the animal-model and treatment-response sections can lean on real experimental evidence rather than hand-waving. Just remember to run everything through fetch-reference / validate-terms before it lands in a YAML — I flagged the two citations (Brain 2018, eLife 2022) where I gave you DOIs instead of PMIDs I couldn't personally confirm.